Tislelizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Tislelizumab and FOLFOX-6 Modified Therapy, 2026, version number 1, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7462/Tislelizumab_and_FOLFOX-6_Modified_Therapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
First-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express programmed death-ligand (PD-L1) with a tumour area positivity (TAP) score >= 5%.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab